Key Highlights

• FY26 Revenue grew 13% to A$10.87 billion, including 5% organic growth, with Underlying EBITDA up 11% to A$1.93 billion

• Underlying Earnings Per Share increased 14% to 125.6 cents, with the total Dividend maintained at A$1.08 per share

• The LADR Laboratory Group Acquisition was completed during the year, with integration progressing and synergy realisation on schedule

Sonic Healthcare(ASX:SHL) closed at A$19.88 on 05 November 2026, gaining 2.63% during the session. The S&P/ASX 200 (XJO) advanced 2.61%, rising 230.60 points to 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) climbed 3.64%, adding 1,240.30 points to 35,329.10. Global Equity markets benefited from overnight Wall Street gains following Democrats' decisive victory in the U.S. midterm elections. Sonic Healthcare is one of the world's largest medical diagnostics companies, providing essential pathology and radiology services to more than 140 million patients annually across nine countries.

FY26 Financial Performance

On 20 August 2026, Sonic Healthcare reported its financial results for the year ended 30 June 2026, achieving its earnings guidance. Revenue rose 13% to A$10,867 million, driven by a combination of 5% organic growth, acquisitions including the LADR Laboratory Group, and contributions from synergy realisation programs.

Underlying EBITDA increased 11% to A$1,933 million, while statutory EBITDA rose 9% to A$1,882 million. Underlying net profit grew 17% to A$621 million, and statutory net profit increased 18% to A$608 million. Underlying earnings per share advanced 14% to 125.6 cents. EBIT margins expanded to over 18%, reflecting Operating Leverage and ongoing synergy capture. Return on invested Capital climbed to 36.5%, up 70 basis points.

Strategic Initiatives and Acquisitions

The completion of the LADR Laboratory Group acquisition represented a major strategic milestone in FY26, with integration progressing well and synergy realisation on schedule. Sonic also continued to capture substantial synergies from earlier acquisitions in Switzerland. The company noted growth in advanced diagnostics leveraging its market-leading brands and capabilities across multiple geographies.

During FY26, Sonic completed a sale and leaseback of its Brisbane hub laboratory as part of a disciplined capital management program and commenced digital and AI transformation initiatives. The progressive dividend was maintained, increasing 1 cent to a total of A$1.08 per share for the year.

About Sonic Healthcare

Sonic Healthcare is a global medical diagnostics company headquartered in Sydney, Australia, listed on the ASX under the ticker SHL. The company operates across nine countries and 11 markets, providing pathology, radiology, and clinical services. It is distinguished by its Medical Leadership model, which places clinicians at the centre of operational decision-making. The company employs approximately 47,000 people globally.

Sector Context

The ASX healthcare sector posted broad gains during the 05 November session, with the Health Care sub-index outperforming the broader market. The global diagnostics industry continues to benefit from growing test volumes driven by ageing populations, increasing disease prevalence, and the expansion of advanced molecular and genetic testing capabilities.

Risks

Key risks for Sonic Healthcare include regulatory and reimbursement changes across its diverse operating geographies, particularly in markets with government-funded healthcare systems. Currency exposure across nine countries presents ongoing translation and transaction risks. The integration of acquisitions, including the LADR Laboratory Group, carries execution risk. The company also faces competitive pressures from other large diagnostics operators and emerging digital health platforms.

Catalysts on Watch

Investors will monitor the delivery of LADR synergies and Swiss acquisition synergy capture. The progress of Sonic's digital and AI transformation program could be a differentiator in the medium term. Organic growth trends, particularly in advanced diagnostics, and any additional acquisition activity will also be key catalysts, alongside the trajectory of EBIT margins and return on invested capital.

The Outlook

Sonic Healthcare's FY26 result demonstrated the benefits of its diversified global platform, with revenue and earnings growth driven by organic expansion, acquisitions, and synergy realisation. With a progressive dividend maintained and new digital initiatives underway, the company enters FY27 with what management has described as a focus on organic growth, efficiency, innovation, and disciplined capital management.